Cuban Drug HeberprotP Authorized To Clinical Trial in the US | News [Video]

The Cuban drug Heberprot-p received authorization for the development of a clinical trial in the U.S. . At the end of the year, the Biocubafarma Business Group announced on its Facebook page.

RELATED:

Cuban Ozonated Soaps: Another Achievement of Science in Cuba

Biocubafarma explained that Discovery Therapeutics Caribe (DTC), an American company specialized in biotechnology, will be in charge of conducting clinical trials with this novel Cuban medicine to treat diabetic foot.

As the Granma newspape details “In the first quarter of 2024, DTC filed an application for a new investigational drug with the US Food and Drug Administration. USA. (FDA) , which included a Phase III protocol for a randomized, double-blind, placebo-controlled trial of Biocubafarma’s leading product.”

Granma also points out that although rhegf (rhegf) is already available in more than 20 countries, this is the first time it will be studied in American patients suffering from diabetic foot ulcers (UPD).

The Pan American Health Organization (PAHO) highlights that …